The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S1-S2 , September 2007

Introduction

  • Scott M. Grundy, MD, PhD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Scott M. Grundy, MD, PhD, Center for Human Nutrition, Department of Clinical Nutrition, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas, 75390-9052.

References 

  1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–1200
  2. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation. 2006;113:2914–2918
  3. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210–1214
  4. Grundy SM. Diabetes and coronary risk equivalency: what does it mean?. Diabetes Care. 2006;29:457–460
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  6. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C Conference Participants. NHLBI/AHA Conference Proceedings: definition of metabolic syndrome (Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition). Circulation. 2004;109:433–438
  7. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism, endorsed by the American College of Cardiology Foundation. Circulation. 2004;110:2952–2967
  8. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6(suppl 2):51S–209S
  9. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138–1145
  10. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529
  11. Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, common sense cure. Lancet. 2002;360:473–482
  12. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093–1100
  13. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care. 2006;29:404–409
  14. Knowler WC, Barett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  15. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994–1003
  16. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs. 2004;64:2845–2864
  17. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience for the RIO-Europe study. Lancet. 2005;365:1389–1397
  18. Despres JP, Golay A, Sjostrom L Rimonabant In Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134
  19. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J RIO-North American Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America (A randomized controlled trial). JAMA. 2006;295:761–775
  20. Scheen A, et al. Effects of rimonabant on type 2 diabetes: RIO-Diabetes. In: Program and Abstracts of the American Diabetes Association 65th Annual Scientific Sessions; June 12, 2005; San Diego, California.
  21. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359

PII: S0002-9343(07)00542-6

doi: 10.1016/j.amjmed.2007.06.004

The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S1-S2 , September 2007

Article Tools